Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing

Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology letters 2021-02, Vol.21 (2), p.169-169, Article 169
Hauptverfasser: Lin, Po-Hung, Huang, Chao-Yuan, Yu, Kai-Jie, Kan, Hung-Cheng, Liu, Chung-Yi, Chuang, Cheng-Keng, Lu, Yu-Chuan, Chang, Ying-Hsu, Shao, I-Hung, Pang, See-Tong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 169
container_issue 2
container_start_page 169
container_title Oncology letters
container_volume 21
creator Lin, Po-Hung
Huang, Chao-Yuan
Yu, Kai-Jie
Kan, Hung-Cheng
Liu, Chung-Yi
Chuang, Cheng-Keng
Lu, Yu-Chuan
Chang, Ying-Hsu
Shao, I-Hung
Pang, See-Tong
description Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were , protein polybromo-1 ( ), histone-lysine N-methyltransferase , BRCA1-associated protein-1 ( ), lysine-specific demethylase 5C ( ), and . The association between the gene mutation status of and was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower and mutation rates compared with average, with increased mutation rates for and . mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The and mutations were mutually exclusive to mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.
doi_str_mv 10.3892/ol.2021.12430
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651395123</galeid><sourcerecordid>A651395123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXbI1dkCQlxydYfcWJfkKoKClIlLvTCxZp1JllXXrvYCRL8ehx2u3QR9sFj-5mxZ-atqleMroTS_DL6FaecrRhvBH1WnbJO85pRxZ8f7K45qS5yvqdlyJYp1b6sToRoZCsbeVp9u8EQt84Su4EEdsLkfsHkYiBxINYjJGLRe5IwgN-ZFpJ1xQnInF0YyQRpxAl7MmJAkvH7jKEA43n1YgCf8WK_nlV3Hz98vf5U3365-Xx9dVtbycRUSyWlBjYIYFJ0YDvdKlb268b2FhqLaNeaD4qtey56RqVqKdVaWQ3FRXFxVr3fxX2Y11vsLYYpgTcPyW0h_TQRnDm-CW5jxvjDdIpyyZoS4N0-QIrl83kyW5eXVCFgnLPhTae6TtOGFfTNP-h9nFMpzZ4qde34X2oEj8aFIZZ37RLUXLUlaS0ZF4Va_Ycqs8fSkBhwcOX8yOHtE4cNgp82Ofp5aVc-BusdaFPMOeFwKAajZhGOid4swjF_hFP4108reKAfZSJ-A3pwvHU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478734572</pqid></control><display><type>article</type><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><source>Spandidos Publications Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</creator><creatorcontrib>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</creatorcontrib><description>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were , protein polybromo-1 ( ), histone-lysine N-methyltransferase , BRCA1-associated protein-1 ( ), lysine-specific demethylase 5C ( ), and . The association between the gene mutation status of and was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower and mutation rates compared with average, with increased mutation rates for and . mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The and mutations were mutually exclusive to mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2021.12430</identifier><identifier>PMID: 33456545</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Angiogenesis ; Cancer ; Carcinoma, Renal cell ; Deoxyribonucleic acid ; DNA ; Epigenetics ; Gene mutations ; Genes ; Genetic aspects ; Growth factors ; Hypoxia ; Kidney cancer ; Kinases ; Lysine ; Metastasis ; Methyltransferases ; Mutation ; Oncology ; Pathology ; Proteins ; Tumor proteins</subject><ispartof>Oncology letters, 2021-02, Vol.21 (2), p.169-169, Article 169</ispartof><rights>Copyright: © Lin et al.</rights><rights>COPYRIGHT 2021 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2021</rights><rights>Copyright: © Lin et al. 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</citedby><orcidid>0000-0001-8245-4302</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802514/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802514/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33456545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Po-Hung</creatorcontrib><creatorcontrib>Huang, Chao-Yuan</creatorcontrib><creatorcontrib>Yu, Kai-Jie</creatorcontrib><creatorcontrib>Kan, Hung-Cheng</creatorcontrib><creatorcontrib>Liu, Chung-Yi</creatorcontrib><creatorcontrib>Chuang, Cheng-Keng</creatorcontrib><creatorcontrib>Lu, Yu-Chuan</creatorcontrib><creatorcontrib>Chang, Ying-Hsu</creatorcontrib><creatorcontrib>Shao, I-Hung</creatorcontrib><creatorcontrib>Pang, See-Tong</creatorcontrib><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were , protein polybromo-1 ( ), histone-lysine N-methyltransferase , BRCA1-associated protein-1 ( ), lysine-specific demethylase 5C ( ), and . The association between the gene mutation status of and was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower and mutation rates compared with average, with increased mutation rates for and . mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The and mutations were mutually exclusive to mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</description><subject>Angiogenesis</subject><subject>Cancer</subject><subject>Carcinoma, Renal cell</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epigenetics</subject><subject>Gene mutations</subject><subject>Genes</subject><subject>Genetic aspects</subject><subject>Growth factors</subject><subject>Hypoxia</subject><subject>Kidney cancer</subject><subject>Kinases</subject><subject>Lysine</subject><subject>Metastasis</subject><subject>Methyltransferases</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Proteins</subject><subject>Tumor proteins</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk1v1DAQhiMEolXbI1dkCQlxydYfcWJfkKoKClIlLvTCxZp1JllXXrvYCRL8ehx2u3QR9sFj-5mxZ-atqleMroTS_DL6FaecrRhvBH1WnbJO85pRxZ8f7K45qS5yvqdlyJYp1b6sToRoZCsbeVp9u8EQt84Su4EEdsLkfsHkYiBxINYjJGLRe5IwgN-ZFpJ1xQnInF0YyQRpxAl7MmJAkvH7jKEA43n1YgCf8WK_nlV3Hz98vf5U3365-Xx9dVtbycRUSyWlBjYIYFJ0YDvdKlb268b2FhqLaNeaD4qtey56RqVqKdVaWQ3FRXFxVr3fxX2Y11vsLYYpgTcPyW0h_TQRnDm-CW5jxvjDdIpyyZoS4N0-QIrl83kyW5eXVCFgnLPhTae6TtOGFfTNP-h9nFMpzZ4qde34X2oEj8aFIZZ37RLUXLUlaS0ZF4Va_Ycqs8fSkBhwcOX8yOHtE4cNgp82Ofp5aVc-BusdaFPMOeFwKAajZhGOid4swjF_hFP4108reKAfZSJ-A3pwvHU</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Lin, Po-Hung</creator><creator>Huang, Chao-Yuan</creator><creator>Yu, Kai-Jie</creator><creator>Kan, Hung-Cheng</creator><creator>Liu, Chung-Yi</creator><creator>Chuang, Cheng-Keng</creator><creator>Lu, Yu-Chuan</creator><creator>Chang, Ying-Hsu</creator><creator>Shao, I-Hung</creator><creator>Pang, See-Tong</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8245-4302</orcidid></search><sort><creationdate>20210201</creationdate><title>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</title><author>Lin, Po-Hung ; Huang, Chao-Yuan ; Yu, Kai-Jie ; Kan, Hung-Cheng ; Liu, Chung-Yi ; Chuang, Cheng-Keng ; Lu, Yu-Chuan ; Chang, Ying-Hsu ; Shao, I-Hung ; Pang, See-Tong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-58559a1f3a1537ac79681a1fb4cdca4ceecb92f81bd23d1058600998c9a3a1823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Angiogenesis</topic><topic>Cancer</topic><topic>Carcinoma, Renal cell</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epigenetics</topic><topic>Gene mutations</topic><topic>Genes</topic><topic>Genetic aspects</topic><topic>Growth factors</topic><topic>Hypoxia</topic><topic>Kidney cancer</topic><topic>Kinases</topic><topic>Lysine</topic><topic>Metastasis</topic><topic>Methyltransferases</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Proteins</topic><topic>Tumor proteins</topic><toplevel>online_resources</toplevel><creatorcontrib>Lin, Po-Hung</creatorcontrib><creatorcontrib>Huang, Chao-Yuan</creatorcontrib><creatorcontrib>Yu, Kai-Jie</creatorcontrib><creatorcontrib>Kan, Hung-Cheng</creatorcontrib><creatorcontrib>Liu, Chung-Yi</creatorcontrib><creatorcontrib>Chuang, Cheng-Keng</creatorcontrib><creatorcontrib>Lu, Yu-Chuan</creatorcontrib><creatorcontrib>Chang, Ying-Hsu</creatorcontrib><creatorcontrib>Shao, I-Hung</creatorcontrib><creatorcontrib>Pang, See-Tong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Po-Hung</au><au>Huang, Chao-Yuan</au><au>Yu, Kai-Jie</au><au>Kan, Hung-Cheng</au><au>Liu, Chung-Yi</au><au>Chuang, Cheng-Keng</au><au>Lu, Yu-Chuan</au><au>Chang, Ying-Hsu</au><au>Shao, I-Hung</au><au>Pang, See-Tong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>21</volume><issue>2</issue><spage>169</spage><epage>169</epage><pages>169-169</pages><artnum>169</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Kidney cancer is one of the most lethal cancer types worldwide. The most common subtype of kidney cancer is clear cell renal cell carcinoma (ccRCC), and the somatic mutations of ccRCC have been identified through the development of large databases. The present study aimed to validate the status of the associated gene mutations in a Taiwanese cohort. Targeted sequencing was used to validate the mutation status of genes related to ccRCC in Taiwanese patients who had nephrectomy for kidney cancer. The top eight mutated genes in the Catalogue Of Somatic Mutations In Cancer (COSMIC) were selected. These genes were , protein polybromo-1 ( ), histone-lysine N-methyltransferase , BRCA1-associated protein-1 ( ), lysine-specific demethylase 5C ( ), and . The association between the gene mutation status of and was validated with clinicopathological parameters as well as overall survival time. Tumor cells from 96 patients with ccRCC were target sequenced. The order of mutation rate of the eight aforementioned genes was similar to that reported within COSMIC. The present Taiwanese cohort exhibited lower and mutation rates compared with average, with increased mutation rates for and . mutation was associated with the tumor and cancerous stage. None of these four genes were positively associated with the overall survival of patients. The and mutations were mutually exclusive to mutation. Overall, the present study provided data confirming gene alteration in Taiwanese patients with ccRCC and showed some differences when compared with Western countries. Further comprehensive genomic and epigenomic studies, as well as downstream validation, are necessary to evaluate the impact of these differences.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>33456545</pmid><doi>10.3892/ol.2021.12430</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8245-4302</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2021-02, Vol.21 (2), p.169-169, Article 169
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7802514
source Spandidos Publications Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Angiogenesis
Cancer
Carcinoma, Renal cell
Deoxyribonucleic acid
DNA
Epigenetics
Gene mutations
Genes
Genetic aspects
Growth factors
Hypoxia
Kidney cancer
Kinases
Lysine
Metastasis
Methyltransferases
Mutation
Oncology
Pathology
Proteins
Tumor proteins
title Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A26%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genomic%20characterization%20of%20clear%20cell%20renal%20cell%20carcinoma%20using%20targeted%20gene%20sequencing&rft.jtitle=Oncology%20letters&rft.au=Lin,%20Po-Hung&rft.date=2021-02-01&rft.volume=21&rft.issue=2&rft.spage=169&rft.epage=169&rft.pages=169-169&rft.artnum=169&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2021.12430&rft_dat=%3Cgale_pubme%3EA651395123%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478734572&rft_id=info:pmid/33456545&rft_galeid=A651395123&rfr_iscdi=true